Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,511,505
  • Shares Outstanding, K 834,772
  • Annual Sales, $ 3,350 M
  • Annual Income, $ 668,000 K
  • EBIT $ 820 M
  • EBITDA $ 998 M
  • 60-Month Beta 0.51
  • Price/Sales 3.16
  • Price/Cash Flow 13.80
  • Price/Book 3.11

Options Overview Details

View History
  • Implied Volatility 50.94% ( -2.96%)
  • Historical Volatility 33.63%
  • IV Percentile 65%
  • IV Rank 37.91%
  • IV High 108.04% on 12/16/24
  • IV Low 16.08% on 05/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 682
  • Open Int (30-Day) 641

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.20
  • Number of Estimates 1
  • High Estimate 0.20
  • Low Estimate 0.20
  • Prior Year 0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.26 +12.48%
on 04/09/25
14.02 -1.61%
on 04/24/25
+0.34 (+2.53%)
since 03/25/25
3-Month
12.26 +12.48%
on 04/09/25
14.04 -1.78%
on 02/06/25
-0.22 (-1.57%)
since 01/24/25
52-Week
12.26 +12.48%
on 04/09/25
16.89 -18.36%
on 08/09/24
-1.01 (-6.85%)
since 04/25/24

Most Recent Stories

More News
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 42.4000 (+3.47%)
RDY : 13.79 (-1.50%)
TEVA : 14.87 (+1.02%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 42.4000 (+3.47%)
RDY : 13.79 (-1.50%)
TEVA : 14.87 (+1.02%)
2 overlooked stocks that crushed earnings but traded lower

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

WHR : 77.40 (-1.99%)
BAC : 39.69 (+0.28%)
RDY : 13.79 (-1.50%)
NVS : 112.14 (+0.87%)
TEVA : 14.87 (+1.02%)
HSBC : 55.99 (+0.52%)
DB : 25.69 (+1.94%)
PFE : 22.92 (+0.61%)
BMY : 47.90 (-1.62%)
Chart of the Day: What's Cooking at Dr. Reddy's Lab

The Chart of the Day belongs to integrated drug company Dr. Reddy's Laboratories (RDY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy...

RDY : 13.79 (-1.50%)
Drugmaker GSK: Becoming a Healthier Value Stock

Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.

RDY : 13.79 (-1.50%)
GSK : 37.43 (-0.19%)
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection...

RDY : 13.79 (-1.50%)
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Treprostinil Injection...

RDY : 13.79 (-1.50%)
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce...

RDY : 13.79 (-1.50%)
ADTX : 2.30 (unch)
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells...

RDY : 13.79 (-1.50%)
COYA : 6.18 (-5.36%)
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

RDY : 13.79 (-1.50%)
COYA : 6.18 (-5.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 13.98
2nd Resistance Point 13.90
1st Resistance Point 13.85
Last Price 13.79
1st Support Level 13.72
2nd Support Level 13.64
3rd Support Level 13.59

See More

52-Week High 16.89
Fibonacci 61.8% 15.12
Fibonacci 50% 14.58
Fibonacci 38.2% 14.03
Last Price 13.79
52-Week Low 12.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar